AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis

AbbVie CEO Rick Gonzalez told investors and analysts on the pharma’s Q4 call this morning that AbbVie expects to add several new indications to Skyrizi and Rinvoq’s “list of approved uses” over the next few months. For Skyrizi, they got the FDA’s OK a few weeks ago to use the drug for psoriatic arthritis — and they’re also looking for the thumbs up from the agency on Crohn’s disease.